Pemetinib/pemetinib’s domestic launch time and purchase method

Pemigatinib is a small molecule inhibitor targeting fibroblast growth factor receptor (FGFR) 1, 2, and 3. It is mainly used to treat patients with advanced or recurrent intrahepatic cholangiocarcinoma who are confirmed to have FGFR2 fusion or rearrangement mutations. As the world's first FGFR inhibitor approved for cholangiocarcinoma, its launch has attracted widespread attention from the global medical community. In China, pemetinib was approved by the State Food and Drug Administration for official marketing in 2023, marking a new stage of personalized targeted therapy for domestic biliary tract cancer.

Regarding the purchase method, pemetinib can currently be prescribed and purchased in some tertiary hospitals, oncology hospitals and pharmacies through distribution channels in China. Patients need to obtain prescriptions from professional doctors before they can obtain drugs, and must be confirmed by molecular testing to be positive for FGFR2 gene fusion mutations. This requirement is because pemetinib is only effective for patients with cholangiocarcinoma who are positive for specific molecular targets, and the medication must be accurately matched. When purchasing, it is recommended to go to an institution with formal drug sales qualifications to ensure the quality and legality of the drugs.

Since this drug has not yet entered the national medical insurance catalog, the price is still relatively high. The common domestic specifications are4.5mg or 9mg, with 14 tablets per box, and the price may range from RMB 20,000 to RMB 50,000. In actual treatment, in addition to paying attention to drug prices and purchase channels, patients also need to pay attention to the overall design of the treatment plan. Pemetinib is a continuous oral treatment drug. Side effects such as hyperphosphatemia, rash, fatigue, etc. need to be closely monitored during medication. If necessary, the dose should be adjusted or a combination medication strategy should be adopted. Therefore, it is recommended that all patients who are willing to use pemetinib consult a doctor and receive complete molecular testing and individualized treatment recommendations before taking the drug.

Reference materials:https://go.drugbank.com/drugs/DB15102